Dr. Rebecca Shatsky & Dr. Reva Basho - Sequencing PI3K/AKT Therapies in Metastatic Breast Cancer

Community Health Media · May 8, 2026 · 26m

How are clinicians navigating the growing number of targeted therapy options in HR-positive, HER2-negative metastatic breast cancer?

In this CHM Conversations episode, Drs. Rebecca Shatsky and Reva Basho discuss the critical role of genomic profiling—specifically PIK3CA, AKT, PTEN, and ESR1—in guiding second-line treatment for HR+/HER2- metastatic breast cancer.

The panel compares the clinical use of alpelisib, capivasertib, and inavolisib, focusing on how to sequence these agents after progression on CDK4/6 inhibitors. The experts share practical strategies for managing class-specific…